Literature DB >> 10366048

Human papillomavirus with co-existing vulvar vestibulitis syndrome and vestibular papillomatosis.

M Origoni1, M Rossi, D Ferrari, F Lillo, A G Ferrari.   

Abstract

OBJECTIVE: The role of HPV infection in cases of vulvar papillomatosis and vulvar vestibulitis syndrome is still unclear and data from the literature is controversial. In this study we intended to investigate the prevalence of viral infection, with a multidisciplinary approach, in cases with a co-existence of the two patterns.
METHOD: Sixteen consecutive cases with diagnosis of vulvar vestibulitis syndrome and co-existence of vestibular papillomatosis were enrolled in the study and investigated by the means of vulvar cytology, vulvoscopy, histology, ViraPap and Polymerase Chain Reaction. RESULT: Cytology, vulvoscopy and histology did not demonstrate suitable accuracy for the diagnosis. Viral DNA identification revealed two (12.50%) positive cases using PCR and one (6.25%) positive case with ViraPap.
CONCLUSION: The results of the present investigation indicate that even in cases of co-existing vulvar papillomatosis and severe vulvar vestibulitis syndrome, the prevalence of HPV infection is too low to be considered causal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366048     DOI: 10.1016/s0020-7292(98)00156-8

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  3 in total

1.  Benign vulvar vestibular papillomatosis: An underreported condition in Indian dermatological literature.

Authors:  Sushil Kakkar; Prafulla K Sharma
Journal:  Indian Dermatol Online J       Date:  2017 Jan-Feb

2.  Case-control study of vulvar vestibulitis risk associated with genital infections.

Authors:  Elaine M Smith; Justine M Ritchie; Rudolph Galask; Erica E Pugh; Jian Jia; Joan Ricks-McGillan
Journal:  Infect Dis Obstet Gynecol       Date:  2002

3.  Monomorphic Papillae on Inner Labia and Vulvar Vestibule.

Authors:  Sushil Kakkar; Prafulla K Sharma
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.